Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) commonly used to relieve pain, inflammation, and stiffness associated with osteoarthritis and rheumatoid arthritis. It works by inhibiting cyclooxygenase (COX) enzymes, reducing the production of prostaglandins, which are responsible for pain and inflammation. As a non-acidic NSAID, nabumetone carries a relatively lower risk of gastrointestinal side effects compared to traditional NSAIDs. The drug is usually administered once daily, improving patient compliance and convenience for long-term therapy. After ingestion, it is metabolized in the liver to its active form, 6-methoxy-2-naphthylacetic acid, which exerts the therapeutic effects. Nabumetone exhibits analgesic, anti-inflammatory, and antipyretic properties, making it suitable for chronic management of joint disorders. Its pharmacokinetic profile supports sustained relief with minimal dosing. It is often preferred in patients who require prolonged NSAID therapy due to its tolerability. Ongoing research explores novel formulations and optimized dosing strategies to further enhance its clinical benefits. Overall, nabumetone is an effective and well-tolerated option for managing inflammatory joint conditions.
